Strain Name:

STOCK Spi1tm1.3Dgt/J

Stock Number:

006083

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names STOCK Sfpi1tm1.3Dgt/J    (Changed: 30-JUL-13 )
Type Mutant Stock; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
Generation?+F1pN1
Generation Definitions
 
Donating Investigator Daniel G. Tenen,   Beth Israel Deaconess Medical Center

Description
Mice homozygous for this targeted deletion are viable and fertile as young animals. Mice on this stock (predominantly 129Sv) background often die between 3-8 months of age of a rapidly developing T cell lymphoma (64% penetrance) or between 6-12 months of acute myeloid lymphoma (AML) (29% penetrance). Homozygotes (termed PU.1 knockdown or UREdelta) have an 80% reduction of endogneous gene expression. This is associated with an accumulation of hematopoietic stem cell precursor cells and neutrophils in bone marrow and spleen. Bone marrow cells from homozygous mice have abnormal responses to myeloid cytokines, and malignant transformation is associated with clonal chromosomal abnormalities. Homozygous mice have abnormal B- and T-cell populations and lineage commitment. These mice may be useful in studing T cell lymphoma, AML and other cancers, transcription factors, and development of multiple cell lineages.

Of note, the latency and penetrance of disease is slightly different from those homozygous mice harboring the URE deletion (and neo cassette) on a mixed BALB/c, C57BL/6, and 129 background (see Sfpi1tm1.1 mice described in Rosenbauer 2004 Nat Genet 36:624).

Development
A targeting vector was designed to place a loxP site on both sides of the 3.4 kb upstream regulatory element (URE) located 14 kb upstream of the endogenous gene. This also inserted a FRT-flanked PGKneo cassette immediately upstream of the loxP-flanked genome. The construct was electroporated into (129X1/SvJ x 129S1/Sv)F1-derived R1 embryonic stem (ES) cells. Chimeric mice were interbred or crossed to C57BL/6 females, resulting in mutant -14kb UREloxP+neo (or Sfpi1tm1Dgt) mice. These were next crossed with BALB/c mice carrying the CMV-cre transgene to excise the URE, creating UREdelta-neo (also called deltaURE-neo, Sfpi1tm1.1). The neomycin resistance cassette was next removed by breeding heterozygous UREdelta-neo mutants on a mixed (but predominantly BALB/c) background with 129Sv mice carrying a "ROSA-FLP" transgene. The resulting offspring (on a mixed, but predominantly 129Sv, background) with the endogenous -14kb upstream regulatory element now replaced with a single FRT and loxP site were maintained by breeding heterozygotes prior to arrival at The Jackson Laboratory.

Control Information

  Control
   Heterozygote from the colony
   Wild-type from the colony
 
  Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of Spi1
006922   B6.Cg-Spi1tm2Dgt/J
006099   B6;129-Spi1tm1.2Dgt/J
006147   B6;FVB-Tg(Sfpi1,-EGFP)7Dgt/J
View Strains carrying other alleles of Spi1     (3 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.
Leukemia, Acute Myeloid; AML
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Spi1tm1.3Dgt/Spi1tm1.3Dgt

        involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6
  • mortality/aging
  • premature death
    • > 90% of mice homozygous for this mutation die between 3 and 13 months of age   (MGI Ref ID J:106040)
  • tumorigenesis
  • increased T cell derived lymphoma incidence
    • in 40% of mice with thymic lymphoma, lymphoma cells are present in the periphery where they greatly elevate peripheral blood lymphocyte numbers, form spleen and/or lymph node tumors, and invade nonhematopoietic organs   (MGI Ref ID J:106040)
    • T-cell lymphoma cells of homozygous mutant mice vary in their expression of CD4 and CD8 and are CD3dim   (MGI Ref ID J:106040)
    • lymphoma cells of mutant mice express terminal deoxynucleotide transferase, a characteristic of immature T lymphoblast cells   (MGI Ref ID J:106040)
    • the lymphoma cells, unlike ordinary T-cell progenitor cells in these mice, express only low levels of PU.1/SFPI1   (MGI Ref ID J:106040)
    • analysis of the TCR-beta variable-region isotype of T-cell lymphoma cells from lymph node tumors indicates they are clonally derived   (MGI Ref ID J:106040)
    • a characteristic pattern of promoter hypermethylation is detected by RLGS analysis in T-cell lymphomas (but not in myeloid tumors) of homozygous mutant mice   (MGI Ref ID J:106040)
    • hypermethylation and transcriptional downregulation of the inhibitor of DNA binding 4 (Id4) tumor suppressor gene is characteristic of T-cell lymphomas, but not of myeloid tumors, of homozygous mutant mice   (MGI Ref ID J:106040)
    • T-cell lymphomas of these mice exhibit a characteristic pattern of promoter hypermethylation that is not shared by myeloid tumors in the same mice; inhibitor of DNA binding 4 (Id4, aka Idb4) is reproducibly hypermethylated and downregulated in these but not AML   (MGI Ref ID J:106040)
    • injection of lymphoma cells transmits the phenoytpe to NOD.CB17-Prkdcscid mice, causing death within 3-6 weeks   (MGI Ref ID J:106040)
  • increased leukemia incidence
    • between 6 and 12 months of age, 29.0% of homozygous mice develop acute myeloid leukemia (AML)   (MGI Ref ID J:106040)
  • immune system phenotype
  • abnormal T cell subpopulation ratio
    • the proportion of immature, CD4-CD8- (double negative, DN) thymocytes is elevated   (MGI Ref ID J:106040)
    • within the DN thymocyte population, the proportions of early, DN1-DN2 stage thymocytes are elevated, while later, DN3-DN4 stage thymocyte percentages are reduced   (MGI Ref ID J:106040)
    • mutant thymi contain elevated numbers of the earliest T cell lineage-restricted progenitor cells (ETPs, CD3-CD4-CD8-Kitbright), but reduced numbers of proT and preT cells   (MGI Ref ID J:106040)
  • abnormal double-negative T cell morphology
    • SFPI1/PU.1 is expressed at higher levels in mutant than in wild-type ETPs and DN1-DN3 thymocytes, but is turned off in both mutant and wild-type CD4+CD8+ (double positive, DP) thymocytes   (MGI Ref ID J:106040)
  • arrested B cell differentiation
    • B cell differentiation is blocked before the pro-B cell stage in mutant mice, as numbers of bone marrow pro-B cells (Lin-IgM-B220+CD43+) and pre-B cells (Lin-IgM-B220+CD43-) are greatly reduced   (MGI Ref ID J:106040)
  • decreased T cell number
    • numbers of mature CD4+ and CD8+ T cells in the periphery are slightly reduced in mutant mice   (MGI Ref ID J:106040)
    • decreased thymocyte number
      • thymi of mutant mice contain 3.4-fold fewer thymocytes than those of wild-type mice   (MGI Ref ID J:106040)
  • decreased granulocyte number
    • proportion of myeloid cells (Mac1lowIgm-) in the peritoneum diminishes over time   (MGI Ref ID J:106040)
  • decreased mature B cell number
    • mature B cell numbers are greatly reduced in bone marrow, spleen and liver of homozygous mutant mice   (MGI Ref ID J:106040)
    • decreased B-1a cell number
      • the intraperitoneal B1 cell population is skewed toward B1b cells (CD5-), with concomitant reduction of the proportion of B1a cells (CD5+) from the 30-40% seen in wild-type mice to ~10-20% in homozygous mutants   (MGI Ref ID J:106040)
  • decreased pre-B cell number
    • numbers of bone marrow pre-B cells (Lin-IgM-B220+CD43-) are greatly reduced   (MGI Ref ID J:106040)
  • decreased pro-B cell number
    • numbers of bone marrow pro-B cells (Lin-IgM-B220+CD43+) are greatly reduced   (MGI Ref ID J:106040)
  • increased IgM level
    • circulating IgM levels in mutant mice are elevated to 3-fold wild-type levels   (MGI Ref ID J:106040)
  • increased lymphocyte cell number
    • intraperitoneal lymphocyte numbers in mutant mice increase progressively with age, to greater than 3-fold wild-type numbers by 4-8 months   (MGI Ref ID J:106040)
    • increased B-1 B cell number
      • the percentage of physically and functionally normal B1 cells (Mac1lowIgMhighCD43+B7.1+CD23-CD19+B220low) in the peritoneum increases with time   (MGI Ref ID J:106040)
      • B1 cells account for up to 43% of peripheral blood lymphocytes in older mutant mice, although they are not present in blood of wild-type mice   (MGI Ref ID J:106040)
      • Southern blot analysis of peritoneal lymphocytes for IghD-J rearrangements found evidence of clonal B1 cell proliferation in one mutant mouse of 6 studied at ages 6-8 mo   (MGI Ref ID J:106040)
      • increased B-1b cell number
        • the intraperitoneal B1 cell population is skewed toward B1b cells (CD5-), with concomitant reduction of the proportion of B1a cells (CD5+) from the 30-40% seen in wild-type mice to ~10-20% in homozygous mutants   (MGI Ref ID J:106040)
    • increased T cell number
      • peripheral blood T-lymphocyte numbers are greatly elevated in 40% of mice with thymic lymphoma   (MGI Ref ID J:106040)
  • small thymus   (MGI Ref ID J:106040)
  • hematopoietic system phenotype
  • abnormal T cell subpopulation ratio
    • the proportion of immature, CD4-CD8- (double negative, DN) thymocytes is elevated   (MGI Ref ID J:106040)
    • within the DN thymocyte population, the proportions of early, DN1-DN2 stage thymocytes are elevated, while later, DN3-DN4 stage thymocyte percentages are reduced   (MGI Ref ID J:106040)
    • mutant thymi contain elevated numbers of the earliest T cell lineage-restricted progenitor cells (ETPs, CD3-CD4-CD8-Kitbright), but reduced numbers of proT and preT cells   (MGI Ref ID J:106040)
  • abnormal double-negative T cell morphology
    • SFPI1/PU.1 is expressed at higher levels in mutant than in wild-type ETPs and DN1-DN3 thymocytes, but is turned off in both mutant and wild-type CD4+CD8+ (double positive, DP) thymocytes   (MGI Ref ID J:106040)
  • arrested B cell differentiation
    • B cell differentiation is blocked before the pro-B cell stage in mutant mice, as numbers of bone marrow pro-B cells (Lin-IgM-B220+CD43+) and pre-B cells (Lin-IgM-B220+CD43-) are greatly reduced   (MGI Ref ID J:106040)
  • decreased T cell number
    • numbers of mature CD4+ and CD8+ T cells in the periphery are slightly reduced in mutant mice   (MGI Ref ID J:106040)
    • decreased thymocyte number
      • thymi of mutant mice contain 3.4-fold fewer thymocytes than those of wild-type mice   (MGI Ref ID J:106040)
  • decreased granulocyte number
    • proportion of myeloid cells (Mac1lowIgm-) in the peritoneum diminishes over time   (MGI Ref ID J:106040)
  • decreased mature B cell number
    • mature B cell numbers are greatly reduced in bone marrow, spleen and liver of homozygous mutant mice   (MGI Ref ID J:106040)
    • decreased B-1a cell number
      • the intraperitoneal B1 cell population is skewed toward B1b cells (CD5-), with concomitant reduction of the proportion of B1a cells (CD5+) from the 30-40% seen in wild-type mice to ~10-20% in homozygous mutants   (MGI Ref ID J:106040)
  • decreased pre-B cell number
    • numbers of bone marrow pre-B cells (Lin-IgM-B220+CD43-) are greatly reduced   (MGI Ref ID J:106040)
  • decreased pro-B cell number
    • numbers of bone marrow pro-B cells (Lin-IgM-B220+CD43+) are greatly reduced   (MGI Ref ID J:106040)
  • increased IgM level
    • circulating IgM levels in mutant mice are elevated to 3-fold wild-type levels   (MGI Ref ID J:106040)
  • increased lymphocyte cell number
    • intraperitoneal lymphocyte numbers in mutant mice increase progressively with age, to greater than 3-fold wild-type numbers by 4-8 months   (MGI Ref ID J:106040)
    • increased B-1 B cell number
      • the percentage of physically and functionally normal B1 cells (Mac1lowIgMhighCD43+B7.1+CD23-CD19+B220low) in the peritoneum increases with time   (MGI Ref ID J:106040)
      • B1 cells account for up to 43% of peripheral blood lymphocytes in older mutant mice, although they are not present in blood of wild-type mice   (MGI Ref ID J:106040)
      • Southern blot analysis of peritoneal lymphocytes for IghD-J rearrangements found evidence of clonal B1 cell proliferation in one mutant mouse of 6 studied at ages 6-8 mo   (MGI Ref ID J:106040)
      • increased B-1b cell number
        • the intraperitoneal B1 cell population is skewed toward B1b cells (CD5-), with concomitant reduction of the proportion of B1a cells (CD5+) from the 30-40% seen in wild-type mice to ~10-20% in homozygous mutants   (MGI Ref ID J:106040)
    • increased T cell number
      • peripheral blood T-lymphocyte numbers are greatly elevated in 40% of mice with thymic lymphoma   (MGI Ref ID J:106040)
  • small thymus   (MGI Ref ID J:106040)

Spi1tm1.3Dgt/Spi1tm1.3Dgt

        involves: 129 * BALB/c * C57BL/6
  • mortality/aging
  • premature death
    • mice are moribund or die by 3 to 8 months from fatal, aggressive neoplastic disease   (MGI Ref ID J:90331)
  • tumorigenesis
  • increased T cell derived lymphoma incidence
    • T cell lymphomas accompany myeloid leukemia and was the dominant disease in 2 mice   (MGI Ref ID J:90331)
  • increased leukemia incidence
    • mice develop fatal, aggressive neoplastic disease similar to AML (acute myelogenous leukemia)   (MGI Ref ID J:90331)
  • immune system phenotype
  • abnormal spleen morphology
    • abnormal architecture due to expansion of myeloid cells   (MGI Ref ID J:90331)
    • enlarged spleen
      • spleen is 1.5 to 2 times bigger than in wild-type mice   (MGI Ref ID J:90331)
      • increased spleen weight
        • leukemic mice spleens weigh 600 to 1,600mg compared to 80 to 150mg in wild-type mice   (MGI Ref ID J:90331)
      • spleen hyperplasia
        • due to expansion of myeloid cells   (MGI Ref ID J:90331)
  • decreased B cell number
    • mice have fewer B lymphoid cells   (MGI Ref ID J:90331)
  • increased neutrophil cell number
    • at 2 to 3 months of age, neutrophil numbers are increased relative to wild-type mice   (MGI Ref ID J:90331)
  • liver/biliary system phenotype
  • abnormal liver morphology
    • abnormal architecture due to expansion of myeloid cells   (MGI Ref ID J:90331)
    • increased liver weight
      • leukemic mice livers weigh 3.0 to 7.2g compared to 1 to 1.5g in wild-type mice   (MGI Ref ID J:90331)
    • liver hyperplasia
      • due to expansion of myeloid cells   (MGI Ref ID J:90331)
  • cellular phenotype
  • abnormal chromosome number
    • trisomy 15 is common in mice with T cell lymphomas   (MGI Ref ID J:90331)
  • hematopoietic system phenotype
  • abnormal hematopoiesis
    • moribund mice accumulate immature myeloid cells in bone marrow and spleen   (MGI Ref ID J:90331)
    • abnormal proerythroblast morphology
      • mice have fewer erythroid cells   (MGI Ref ID J:90331)
    • decreased B cell number
      • mice have fewer B lymphoid cells   (MGI Ref ID J:90331)
    • increased neutrophil cell number
      • at 2 to 3 months of age, neutrophil numbers are increased relative to wild-type mice   (MGI Ref ID J:90331)
  • abnormal spleen morphology
    • abnormal architecture due to expansion of myeloid cells   (MGI Ref ID J:90331)
    • enlarged spleen
      • spleen is 1.5 to 2 times bigger than in wild-type mice   (MGI Ref ID J:90331)
      • increased spleen weight
        • leukemic mice spleens weigh 600 to 1,600mg compared to 80 to 150mg in wild-type mice   (MGI Ref ID J:90331)
      • spleen hyperplasia
        • due to expansion of myeloid cells   (MGI Ref ID J:90331)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cancer Research
Genes Regulating Growth and Proliferation
Increased Tumor Incidence
      Leukemia
      Leukemia: lymphatic
      Lymphomas

Developmental Biology Research
Internal/Organ Defects
      Lymphoid Tissue Defects
      hematopoietic defects
Lymphoid Tissue Defects
      hematopoietic defects

Hematological Research
Hematopoietic Defects

Immunology, Inflammation and Autoimmunity Research
Lymphoid Tissue Defects
      hematopoietic development

Internal/Organ Research
Lymphoid Tissue Defects

Research Tools
Cancer Research
      Leukemia
      tumor immunology
Hematological Research
Immunology, Inflammation and Autoimmunity Research

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Spi1tm1.3Dgt
Allele Name targeted mutation 1.3, Daniel G Tenen
Allele Type Targeted (knock-out)
Common Name(s) PU.1 knockdown; UREdelta; UREdelta (neo-);
Strain of Origin(129X1/SvJ x 129S1/Sv)F1-Kitl<+>
ES Cell Line NameR1
ES Cell Line Strain(129X1/SvJ x 129S1/Sv)F1-Kitl<+>
Gene Symbol and Name Spi1, spleen focus forming virus (SFFV) proviral integration oncogene
Chromosome 2
Gene Common Name(s) Dis-1; PU.1; SFFV proviral integration 1; Sfpi-1; Sfpi1; Spi-1; Tcfpu1; Tfpu.1; transcription factor PU.1;
General Note Although expression of PU.1/SFPI1 in hematopoietic stem cells, myeloid progenitor cells and granulocytes is similar in mice homozygous for this mutation and for Sfpi1tm1.1Dgt ("UREdeltaneo"), which retains the PGK-neo cassette, mice with the present mutation develop acute myelocytic leukemia (AML) with a lower penetrance (29% vs. 97%) and a longer latency (6-12 months vs. 3-8 months) than do those with Sfpi1tm1.1Dgt. Mice with the present mutation often die of T cell lymphoma before the time of onset of AML. (J:106789;J:90331) The phenotypic difference may be due to genetic background differences, as Sfpi1tm1.1Dgt was analyzed on a ~50% BALB/c and the present mutation on a greater than 50% 129/Sv background.
Molecular Note This allele was generated from Sfpi1tm1Dgt by sequential deletion of the loxP-flanked 3.4-kb upstream regulatory element (URE), located 14 kb upstream from the endogenous gene, and of the FRT-flanked PGK-Neo cassette residing immediately upstream of the URE, achieved by crossing mice bearing the Sfpi1 mutations with animals ubiquitously expressing Cre and FLP recombinase, respectively. Thus it lacks both the normal URE and the introduced PGK-neo cassette, with single loxP and FRT sites markingtheir former locations. Expression of the gene in bone marrow and purified hematopoietic stem cells (HSCs) of homozygous mutant mice is reduced to ~80% of wild-type levels. [MGI Ref ID J:106040] [MGI Ref ID J:106789] [MGI Ref ID J:90331]

Genotyping

Genotyping Information

Genotyping Protocols

Sfpi1tm1.3Dgt, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Rosenbauer F; Owens BM; Yu L; Tumang JR; Steidl U; Kutok JL; Clayton LK; Wagner K; Scheller M; Iwasaki H; Liu C; Hackanson B; Akashi K; Leutz A; Rothstein TL; Plass C; Tenen DG. 2006. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet 38(1):27-37. [PubMed: 16311598]  [MGI Ref ID J:106040]

Additional References

Spi1tm1.3Dgt related

Kawahara M; Pandolfi A; Bartholdy B; Barreyro L; Will B; Roth M; Okoye-Okafor UC; Todorova TI; Figueroa ME; Melnick A; Mitsiades CS; Steidl U. 2012. H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell 22(2):194-208. [PubMed: 22897850]  [MGI Ref ID J:191823]

Leddin M; Perrod C; Hoogenkamp M; Ghani S; Assi S; Heinz S; Wilson NK; Follows G; Schonheit J; Vockentanz L; Mosammam AM; Chen W; Tenen DG; Westhead DR; Gottgens B; Bonifer C; Rosenbauer F. 2011. Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood 117(10):2827-38. [PubMed: 21239694]  [MGI Ref ID J:170517]

Rosenbauer F; Wagner K; Kutok JL; Iwasaki H; Le Beau MM; Okuno Y; Akashi K; Fiering S; Tenen DG. 2004. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36(6):624-30. [PubMed: 15146183]  [MGI Ref ID J:90331]

Steidl U; Rosenbauer F; Verhaak RG; Gu X; Ebralidze A; Otu HH; Klippel S; Steidl C; Bruns I; Costa DB; Wagner K; Aivado M; Kobbe G; Valk PJ; Passegue E; Libermann TA; Delwel R; Tenen DG. 2006. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 38(11):1269-77. [PubMed: 17041602]  [MGI Ref ID J:115331]

Zhang P. 2006. Sfpi1<tm1.3Dgt>(URE-delta [neo-] development Personal Communication :.  [MGI Ref ID J:106789]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, these mice are bred as heterozygotes.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2085.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2710.50
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   Heterozygote from the colony
   Wild-type from the colony
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.5)